MX2024007317A - Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular. - Google Patents
Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular.Info
- Publication number
- MX2024007317A MX2024007317A MX2024007317A MX2024007317A MX2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A MX 2024007317 A MX2024007317 A MX 2024007317A
- Authority
- MX
- Mexico
- Prior art keywords
- surface protein
- discernible
- therapy
- protein variants
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215028 | 2021-12-16 | ||
| EP22164796 | 2022-03-28 | ||
| EP22207926 | 2022-11-16 | ||
| PCT/EP2022/086452 WO2023111311A1 (en) | 2021-12-16 | 2022-12-16 | Discernible cell surface protein variants of cd117 for use in cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007317A true MX2024007317A (es) | 2024-06-26 |
Family
ID=84981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007317A MX2024007317A (es) | 2021-12-16 | 2022-12-16 | Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250057951A1 (https=) |
| EP (1) | EP4448573A1 (https=) |
| JP (1) | JP2024546996A (https=) |
| KR (1) | KR20240115920A (https=) |
| AU (1) | AU2022409748A1 (https=) |
| CA (1) | CA3240527A1 (https=) |
| IL (1) | IL313568A (https=) |
| MX (1) | MX2024007317A (https=) |
| WO (1) | WO2023111311A1 (https=) |
| ZA (1) | ZA202405110B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4540287A1 (en) * | 2022-06-20 | 2025-04-23 | CRISPR Therapeutics AG | Chimeric antigen receptor specific to cd117 |
| KR20250034296A (ko) * | 2022-07-07 | 2025-03-11 | 씨메이오 테라퓨틱스 아게 | Cd117을 표적화하는 항체 |
| WO2025231071A1 (en) * | 2024-05-01 | 2025-11-06 | Beam Therapeutics Inc. | Compositions and methods for cell conditioning |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0578774T3 (da) | 1991-04-05 | 1999-04-26 | Univ Washington | Monoklonale antistoffer mod stamcellefaktor-receptorer |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| AU2017355218B2 (en) | 2016-11-02 | 2024-02-22 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| CA3079215A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| CA3079897A1 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
| US12378318B2 (en) * | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| CN119684457A (zh) | 2018-11-26 | 2025-03-25 | 四十七有限责任公司 | 针对c-kit的人源化抗体 |
| JP2022529727A (ja) * | 2019-04-24 | 2022-06-23 | マジェンタ セラピューティクス インコーポレイテッド | Ａｎｔｉ－ｃｄ１１７ とその使用 |
| US20230017979A1 (en) | 2019-08-29 | 2023-01-19 | Beam Therapeutics Inc. | Compositions and methods for non-toxic conditioning |
-
2022
- 2022-12-16 WO PCT/EP2022/086452 patent/WO2023111311A1/en not_active Ceased
- 2022-12-16 JP JP2024536163A patent/JP2024546996A/ja active Pending
- 2022-12-16 MX MX2024007317A patent/MX2024007317A/es unknown
- 2022-12-16 EP EP22843648.1A patent/EP4448573A1/en active Pending
- 2022-12-16 KR KR1020247023745A patent/KR20240115920A/ko active Pending
- 2022-12-16 AU AU2022409748A patent/AU2022409748A1/en active Pending
- 2022-12-16 US US18/719,780 patent/US20250057951A1/en active Pending
- 2022-12-16 IL IL313568A patent/IL313568A/en unknown
- 2022-12-16 CA CA3240527A patent/CA3240527A1/en active Pending
-
2024
- 2024-06-28 ZA ZA2024/05110A patent/ZA202405110B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250057951A1 (en) | 2025-02-20 |
| JP2024546996A (ja) | 2024-12-26 |
| IL313568A (en) | 2024-08-01 |
| KR20240115920A (ko) | 2024-07-26 |
| ZA202405110B (en) | 2025-12-17 |
| AU2022409748A1 (en) | 2024-05-23 |
| WO2023111311A1 (en) | 2023-06-22 |
| CA3240527A1 (en) | 2023-06-22 |
| EP4448573A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202405110B (en) | Discernible cell surface protein variants of cd117 for use in cell therapy | |
| PH12020552039A1 (en) | Binding molecules against bcma and uses thereof | |
| EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
| NZ595938A (en) | Tumor suppression using placental stem cells | |
| GB2454386A (en) | Method for stem cell culture and cells derived therefrom | |
| MX2012001261A (es) | Medio de cultivo de celula para la expresion de proteina adamts. | |
| BR112014031424A2 (pt) | tratamento de células pluripotentes | |
| MX2008007286A (es) | Ingenieria in vivo de superficie celular. | |
| AU2009240884A8 (en) | Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation | |
| MX339769B (es) | Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos. | |
| MX337041B (es) | Cepas y metodos para mejorar la salud y/o desempeño de los rumiantes. | |
| MX2023006456A (es) | Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos. | |
| DOP2014000294A (es) | Purificación de iduronato 2 sulfatasa | |
| WO2011096728A3 (en) | Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling | |
| CL2022001655A1 (es) | Variantes diseñadas de la alfa-glucosidasa ácida. | |
| MX360085B (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
| SG148171A1 (en) | Methods of proliferating stem cells | |
| WO2020205626A8 (en) | Modulators of cell surface protein interactions and methods and compositions related to same | |
| MX2021003567A (es) | Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia. | |
| WO2018009528A8 (en) | Combination cancer immunotherapies with arginine depletion agents | |
| ZA202405124B (en) | Discernible cell surface protein variants of cd45 for use in cell therapy | |
| WO2020000035A8 (en) | Modified t cells and uses thereof | |
| WO2021101273A3 (ko) | 조절 t 세포 배양용 조성물 및 이의 용도 | |
| PH12021551166A1 (en) | Combination therapy of arms and natural killer cells | |
| WO2021250583A3 (en) | 3d culture of mesenchymal lineage precursor or stem cells |